A Multicenter, Double-Blind, Randomized, Phase 2 Study to Compare the Safety and Efficacy of Intravenous CXA 101/ Tazobactam and Metronidazole With That of Meropenem in Complicated Intraabdominal Infections

Trial Profile

A Multicenter, Double-Blind, Randomized, Phase 2 Study to Compare the Safety and Efficacy of Intravenous CXA 101/ Tazobactam and Metronidazole With That of Meropenem in Complicated Intraabdominal Infections

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Ceftolozane/tazobactam (Primary) ; Meropenem; Metronidazole
  • Indications Bacterial infections; Intra-abdominal infections
  • Focus Therapeutic Use
  • Sponsors Cubist Pharmaceuticals
  • Most Recent Events

    • 13 Sep 2013 Results presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 16 Jun 2011 Primary endpoint 'Clinical-response-rate' has been met according to a Cubist media release..
    • 16 Jun 2011 Results have been reported in a Cubist Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top